Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 15/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759316 | 1.00 | SMYD3 (0.39) | SMYD3POLBEPHX2PKMMMP2 | |
| SCHEMBL18987658 | 1.00 | SMYD3 (0.39) | SMYD3POLBEPHX2PKMMMP2 | |
| SCHEMBL2697870 | 1.00 | SMYD3 (0.39) | SMYD3POLBEPHX2PKMMMP2 | |
| SCHEMBL4196561 | 1.00 | SMYD3 (0.39) | SMYD3POLBEPHX2PKMMMP2 | |
| SCHEMBL2722459 | 1.00 | SMYD3 (0.39) | SMYD3POLBEPHX2PKMMMP2 | |
| SCHEMBL29148282 | 1.00 | SMYD3 (0.39) | SMYD3POLBEPHX2PKMMMP2 | |
| SCHEMBL4930315 | 1.00 | SMYD3 (0.39) | SMYD3POLBEPHX2PKMMMP2 | |
| Hydrochloric Acid SCHEMBL10002329 | 0.98 | SMYD3 (0.38) | SMYD3POLBEPHX2PKM | |
| Hydrochloric Acid SCHEMBL4924986 | 0.98 | SMYD3 (0.38) | SMYD3POLBEPHX2PKM | |
| Hydrochloric Acid SCHEMBL4924981 | 0.98 | SMYD3 (0.38) | SMYD3POLBEPHX2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486758-A | Preparation method of (1S, 3S) -3-aminocycloamyl carbamic acid tert-butyl ester | 南京正济医药研究有限公司 | 2024-02-02 | — | — | CN | claimed |
| EP-4389736-A1 | UREA COMPOUND CONTAINING 2-HETEROAROMATIC RING SUBSTITUTION, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024032747-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| CN-117486758-A | Preparation method of (1S, 3S) -3-aminocycloamyl carbamic acid tert-butyl ester | 南京正济医药研究有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| EP-4218731-A2 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023020209-A1 | UREA COMPOUND CONTAINING 2-HETEROAROMATIC RING SUBSTITUTION, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-02-23 | — | — | WO | disclosed |
| US-11369599-B2 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | ABBVIE INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20140113910-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-8580794-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267534-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-8546399-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120277210-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BRUNCKO MILAN (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120108590-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113910-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMYD3 3251/4885POLB 1831/4885EPHX2 3825/4885 |
| US-20120277210-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | SMYD3 2058/4885POLB 1300/4885EPHX2 4568/4885 |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMYD3 3282/4885POLB 1702/4885EPHX2 3784/4885 |
| US-11369599-B2 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | BCL2, BAX, BCL2L1 | SMYD3 2684/4885POLB 1409/4885EPHX2 4513/4885 |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | SMYD3 3282/4885POLB 1702/4885EPHX2 3784/4885 |
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMYD3 3251/4885POLB 1831/4885EPHX2 3825/4885 |
| US-20090118332-A1 | Therapeutic Agents - 551 | GPR119, FABP4, FASN | SMYD3 3450/4885POLB 2291/4885EPHX2 1775/4885 |
| US-20120108590-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | SMYD3 2799/4885POLB 1464/4885EPHX2 4494/4885 |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMYD3 3251/4885POLB 1831/4885EPHX2 3825/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMYD3 3282/4885POLB 1702/4885EPHX2 3784/4885 |
| US-20130267534-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMYD3 3251/4885POLB 1831/4885EPHX2 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.